For its first fiscal quarter (ending March 31), Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) has reported a 67% increase in E.P.S. from $0.54 a year ago to $0.90 in the current quarter. However, this performance was $-0.19 short of the consensus estimate of $1.09. E.P.S. were $3.20 for the latest four quarters through March 31 versus $1.91 for the same period a year ago — an increase of 68%.
Recent Price Action
Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) stock closed at $42.21 on 5/8/24 after a modest decline of -1.3%. This decline was accompanied by normal trading volume. The stock has risen 2.3% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
AMPH is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Amphastar Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). This rating combines contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Amphastar Pharmaceuticals has a slightly positive Appreciation Score of 62 but a slightly negative Power Rating of 35, leading to the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment